I now have comprehensive content from the textbooks. Let me compile the full answer.
Sex Hormone-Binding Globulin (SHBG)
What is SHBG?
SHBG is an 88 kDa homodimeric glycoprotein (also called testosterone-estrogen-binding globulin / TEBG), produced in the liver, encoded on chromosome 17p13.1. It is an alpha-globulin that binds sex steroids with high affinity but low capacity.
- Harper's Illustrated Biochemistry, 32e
Binding affinities (highest to lowest):
| Steroid | Binding |
|---|
| DHT | Highest affinity |
| Testosterone | High affinity |
| Estradiol | ~5x lower than testosterone |
| Progesterone / Cortisol | Minimal |
Distribution of testosterone in blood:
- 66-78% bound to SHBG - biologically inactive
- 20-32% loosely bound to albumin (bioavailable)
- 1-2% free/unbound (biologically active)
Only the non-SHBG-bound fraction (free + albumin-bound) is considered bioavailable.
- Berek & Novak's Gynecology
Regulators of SHBG Levels
| Increases SHBG | Decreases SHBG |
|---|
| Estrogens (women have 2x SHBG vs men) | Androgens |
| Pregnancy | Hyperinsulinemia / Insulin resistance |
| Oral contraceptives | Obesity |
| Hyperthyroidism | Hypothyroidism |
| Cirrhosis / liver disease | Advancing age |
| Luteal phase | Glucocorticoids, GH, danazol |
When SHBG rises, more testosterone is bound and less is free. When SHBG falls, free testosterone rises even if total testosterone stays the same.
- Harper's Illustrated Biochemistry, 32e; Campbell-Walsh-Wein Urology
Role of SHBG in PCOS
SHBG sits at the intersection of three core pathogenic axes of PCOS: hyperandrogenism, insulin resistance, and obesity.
1. Low SHBG = Amplified Hyperandrogenism
In PCOS, SHBG levels are characteristically reduced. This has two direct consequences:
- The free testosterone fraction is elevated even when total testosterone is only mildly raised or within the normal range
- This free testosterone is what drives clinical features: hirsutism, acne, alopecia, anovulation
Because increases in testosterone production are not proportionately reflected in raised total testosterone levels (since rising androgens simultaneously suppress SHBG), free testosterone is the more sensitive marker of hyperandrogenism in PCOS.
- Berek & Novak's Gynecology
2. Insulin Resistance Suppresses SHBG (Vicious Cycle)
Hyperinsulinemia in PCOS directly suppresses hepatic SHBG synthesis:
-
Insulin collaborates with LH to enhance theca cell androgen production
-
Simultaneously, insulin inhibits hepatic SHBG synthesis, increasing bioavailable testosterone
-
More free testosterone worsens hyperandrogenism, which further suppresses SHBG
-
This creates a self-amplifying loop: Insulin ↑ → SHBG ↓ → Free T ↑ → Androgen effects ↑
-
Berek & Novak's Gynecology, p. 1927
3. Genetic Association
GWAS and linkage studies have identified the SHBG gene locus as a likely PCOS candidate gene, alongside insulin receptor, IRS-1, IRS-2, and TCF7L2 loci. This suggests a genetic predisposition to intrinsically low SHBG may contribute to PCOS susceptibility.
- Berek & Novak's Gynecology
4. Diagnostic Utility
- Low SHBG (or high free androgen index [FAI] = Total T / SHBG × 100) is a key biochemical marker of PCOS
- The Free Androgen Index (FAI) is a practical surrogate for free testosterone and is commonly elevated in PCOS
- Measuring SHBG + total testosterone allows estimation of free testosterone without the expensive gold-standard equilibrium dialysis method
5. Response to Treatment - SHBG as a Therapeutic Monitor
| Intervention | Effect on SHBG |
|---|
| Weight loss >5-15% | SHBG rises (improved) |
| Combined OCP | SHBG rises markedly |
| Metformin / insulin sensitizers | SHBG rises (via reducing insulin) |
| Spironolactone | Modest SHBG rise |
| Lifestyle/exercise | SHBG improves with insulin sensitivity |
A rising SHBG is a useful biochemical endpoint of treatment success in PCOS.
- Berek & Novak's Gynecology, p. 1930
Clinical Summary
Low SHBG in PCOS
↓
More free testosterone → Hirsutism, acne, anovulation
↑
Insulin resistance → Suppresses hepatic SHBG
↑
Obesity + PCOS (synergistic on IR)
SHBG is both a biomarker of androgenic activity and a mediator of the insulin-androgen axis in PCOS. Its measurement (or calculation of FAI) is standard in the biochemical workup of PCOS, and its normalization is a goal of lifestyle and pharmacological therapy.